
## Kazuhiro Komura

List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/4681968/publications.pdf Version: 2024-02-01



KAZUHIDO KOMUDA

#	Article	IF	CITATIONS
1	Common and Distinct Clinical Features in Adult Patients with Anti-Aminoacyl-tRNA Synthetase Antibodies: Heterogeneity within the Syndrome. PLoS ONE, 2013, 8, e60442.	2.5	306
2	Clinical Correlations With Dermatomyositis-Specific Autoantibodies in Adult Japanese Patients With Dermatology, 2011, 147, 391.	1.4	293
3	Identification of a novel autoantibody reactive with 155 and 140 kDa nuclear proteins in patients with dermatomyositis: an association with malignancy. Rheumatology, 2007, 46, 25-28.	1.9	277
4	Antibody isotype-specific engagement of Fcl <sup>3</sup> receptors regulates B lymphocyte depletion during CD20 immunotherapy. Journal of Experimental Medicine, 2006, 203, 743-753.	8.5	238
5	B-Lymphocyte Depletion Reduces Skin Fibrosis and Autoimmunity in the Tight-Skin Mouse Model for Systemic Sclerosis. American Journal of Pathology, 2006, 169, 954-966.	3.8	195
6	CD19 Regulates Skin and Lung Fibrosis via Toll-Like Receptor Signaling in a Model of Bleomycin-Induced Scleroderma. American Journal of Pathology, 2008, 172, 1650-1663.	3.8	192
7	CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. Journal of Clinical Investigation, 2002, 109, 1453-1462.	8.2	188
8	Canonical Wnt signaling induces skin fibrosis and subcutaneous lipoatrophy: A novel mouse model for scleroderma?. Arthritis and Rheumatism, 2011, 63, 1707-1717.	6.7	178
9	PPARÎ <sup>3</sup> Downregulation by TGFß in Fibroblast and Impaired Expression and Function in Systemic Sclerosis: A Novel Mechanism for Progressive Fibrogenesis. PLoS ONE, 2010, 5, e13778.	2.5	158
10	Cell Adhesion Molecules Regulate Fibrotic Process via Th1/Th2/Th17 Cell Balance in a Bleomycin-Induced Scleroderma Model. Journal of Immunology, 2010, 185, 2502-2515.	0.8	126
11	Correlation of IgE Autoantibody to BP180 With a Severe Form of Bullous Pemphigoid. Archives of Dermatology, 2008, 144, 41-8.	1.4	121
12	Treatment with rapamycin prevents fibrosis in tightâ€skin and bleomycinâ€induced mouse models of systemic sclerosis. Arthritis and Rheumatism, 2010, 62, 2476-2487.	6.7	118
13	Clinical association of serum interleukin-17 levels in systemic sclerosis: Is systemic sclerosis a Th17 disease?. Journal of Dermatological Science, 2008, 50, 240-242.	1.9	110
14	Inhibitory Role of CD19 in the Progression of Experimental Autoimmune Encephalomyelitis by Regulating Cytokine Response. American Journal of Pathology, 2006, 168, 812-821.	3.8	109
15	The clinical relevance of serum antinuclear antibodies in Japanese patients with systemic sclerosis. British Journal of Dermatology, 2008, 158, 487-495.	1.5	108
16	Serum pulmonary and activationâ€regulated chemokine/CCL18 levels in patients with systemic sclerosis: A sensitive indicator of active pulmonary fibrosis. Arthritis and Rheumatism, 2005, 52, 2889-2896.	6.7	107
17	Clinical Significance of Serum HMGB-1 and sRAGE Levels in Systemic Sclerosis: Association with Disease Severity. Journal of Clinical Immunology, 2009, 29, 180-189.	3.8	96
18	CD19-dependent B lymphocyte signaling thresholds influence skin fibrosis and autoimmunity in the tight-skin mouse. Journal of Clinical Investigation, 2002, 109, 1453-1462.	8.2	93

KAZUHIRO KOMURA

#	Article	IF	CITATIONS
19	CD19, a Response Regulator of B Lymphocytes, Regulates Wound Healing through Hyaluronan-Induced TLR4 Signaling. American Journal of Pathology, 2009, 175, 649-660.	3.8	84
20	Autoantibody against matrix metalloproteinase-3 in patients with systemic sclerosis. Clinical and Experimental Immunology, 2004, 138, 357-363.	2.6	76
21	Serum soluble CTLA-4 levels are increased in diffuse cutaneous systemic sclerosis. British Journal of Rheumatology, 2004, 43, 1261-1266.	2.3	73
22	CD19 regulates the development of bleomycinâ€induced pulmonary fibrosis in a mouse model. Arthritis and Rheumatism, 2008, 58, 3574-3584.	6.7	73
23	BAFF Antagonist Attenuates the Development of Skin Fibrosis in Tight-Skin Mice. Journal of Investigative Dermatology, 2007, 127, 2772-2780.	0.7	69
24	Increased Serum Soluble OX40 in Patients with Systemic Sclerosis. Journal of Rheumatology, 2008, 35, 2359-2362.	2.0	68
25	A synthetic PPAR-Î <sup>3</sup> agonist triterpenoid ameliorates experimental fibrosis: PPAR-Î <sup>3</sup> -independent suppression of fibrotic responses. Annals of the Rheumatic Diseases, 2014, 73, 446-454.	0.9	62
26	Clinical evaluation of anti-aminoacyl tRNA synthetase antibodies in Japanese patients with dermatomyositis. Journal of Rheumatology, 2007, 34, 1012-8.	2.0	62
27	Platelets Control Leukocyte Recruitment in a Murine Model of Cutaneous Arthus Reaction. American Journal of Pathology, 2010, 176, 259-269.	3.8	57
28	Intercellular Adhesion Molecule-1 and L-Selectin Regulate Bleomycin-Induced Lung Fibrosis. American Journal of Pathology, 2002, 161, 1607-1618.	3.8	55
29	Abnormal Natural Killer Cell Function in Systemic Sclerosis: Altered Cytokine Production and Defective Killing Activity. Journal of Investigative Dermatology, 2005, 125, 731-737.	0.7	55
30	L-Selectin or ICAM-1 Deficiency Reduces an Immediate-Type Hypersensitivity Response by Preventing Mast Cell Recruitment in Repeated Elicitation of Contact Hypersensitivity. Journal of Immunology, 2003, 170, 4325-4334.	0.8	54
31	Elevated serum interleukin-27 levels in patients with systemic sclerosis: association with T cell, B cell and fibroblast activation. Annals of the Rheumatic Diseases, 2011, 70, 194-200.	0.9	54
32	Prevalence and clinical characteristics of anti-Mi-2 antibodies in Japanese patients with dermatomyositis. Journal of Dermatological Science, 2005, 40, 215-217.	1.9	51
33	Blockade of CD40/CD40 ligand interactions attenuates skin fibrosis and autoimmunity in the tight-skin mouse. Annals of the Rheumatic Diseases, 2008, 67, 867-872.	0.9	50
34	Reduced red blood cell velocity in nail-fold capillaries as a sensitive and specific indicator of microcirculation injury in systemic sclerosis. Rheumatology, 2009, 48, 696-703.	1.9	47
35	The Cutaneous Reverse Arthus Reaction Requires Intercellular Adhesion Molecule 1 and L-Selectin Expression. Journal of Immunology, 2002, 168, 2970-2978.	0.8	42
36	Increased Serum Pentraxin 3 in Patients with Systemic Sclerosis. Journal of Rheumatology, 2009, 36, 976-983.	2.0	41

KAZUHIRO KOMURA

#	Article	IF	CITATIONS
37	Endothelial selectins regulate skin wound healing in cooperation with L-selectin and ICAM-1. Journal of Leukocyte Biology, 2007, 82, 519-531.	3.3	39
38	A Clue for Telangiectasis in Systemic Sclerosis: Elevated Serum Soluble Endoglin Levels in Patients with the Limited Cutaneous Form of the Disease. Dermatology, 2006, 213, 88-92.	2.1	38
39	Autoantibodies against matrix metalloproteinase-1 in patients with localized scleroderma. Journal of Dermatological Science, 2008, 52, 47-54.	1.9	38
40	Serum levels of monocyte chemotactic protein-3/CCL7 are raised in patients with systemic sclerosis: association with extent of skin sclerosis and severity of pulmonary fibrosis. Annals of the Rheumatic Diseases, 2006, 65, 124-126.	0.9	37
41	Autoantibody against peroxiredoxin I, an antioxidant enzyme, in patients with systemic sclerosis: possible association with oxidative stress. Rheumatology, 2007, 46, 790-795.	1.9	37
42	Elevated circulating CD40L concentrations in patients with systemic sclerosis. Journal of Rheumatology, 2004, 31, 514-9.	2.0	37
43	Regulation of local and metastatic host-mediated anti-tumour mechanisms by l-selectin and intercellular adhesion molecule-1. Clinical and Experimental Immunology, 2006, 143, 216-227.	2.6	34
44	Autoantibody against one of the antioxidant repair enzymes, methionine sulfoxide reductase A, in systemic sclerosis: association with pulmonary fibrosis and vascular damage. Archives of Dermatological Research, 2010, 302, 27-35.	1.9	33
45	Management of Squamous Cell Carcinoma in a Patient with Recessive-Type Epidermolysis Bullosa Dystrophica. Dermatologic Surgery, 2004, 30, 1424-1429.	0.8	32
46	Usefulness of anti-cyclic citrullinated peptide antibody and rheumatoid factor to detect rheumatoid arthritis in patients with systemic sclerosis. Rheumatology, 2010, 49, 2135-2139.	1.9	32
47	Increased cutaneous T-cell-attracting chemokine levels in sera from patients with systemic sclerosis. Rheumatology, 2005, 44, 873-878.	1.9	29
48	Anti-lipoprotein lipase antibody in systemic sclerosis: association with elevated serum triglyceride concentrations. Journal of Rheumatology, 2005, 32, 629-36.	2.0	29
49	Autoantibody-mediated regulation of B cell responses by functional anti-CD22 autoantibodies in patients with systemic sclerosis. Clinical and Experimental Immunology, 2009, 159, 176-184.	2.6	28
50	Increased Serum Levels of NÉ›-(hexanoyl)lysine, A New Marker of Oxidative Stress, in Systemic Sclerosis. Journal of Rheumatology, 2008, 35, 2214-2219.	2.0	23
51	Autoantibodies to a collagen-specific molecular chaperone, heat-shock protein 47, in systemic sclerosis. Clinical and Experimental Immunology, 2004, 138, 534-539.	2.6	18
52	Autoantibodies against phosphatidylserine-prothrombin complex in patients with systemic sclerosis. Annals of the Rheumatic Diseases, 2004, 63, 1514-1517.	0.9	17
53	P-selectin glycoprotein ligand-1 is required for the development of cutaneous vasculitis induced by immune complex deposition. Journal of Leukocyte Biology, 2004, 76, 374-382.	3.3	15
54	Elevated Serum Concentrations of Polymorphonuclear Neutrophilic Leukocyte Elastase in Systemic Sclerosis: Association with Pulmonary Fibrosis. Journal of Rheumatology, 2009, 36, 99-105.	2.0	15

Kazuhiro Komura

#	Article	IF	CITATIONS
55	Drug-Induced Hypersensitivity Syndrome Associated with Human Herpesvirus 6 and Cytomegalovirus Reactivation. Journal of Dermatology, 2005, 32, 976-981.	1.2	14
56	Decreased levels of autoantibody against histone deacetylase 3 in patients with systemic sclerosis. Autoimmunity, 2009, 42, 120-125.	2.6	14
57	Elevation of IgG levels is a serological indicator for pulmonary fibrosis in systemic sclerosis with anti-topoisomerase I antibodies and those with anticentromere antibody. Clinical and Experimental Dermatology, 2008, 33, 329-332.	1.3	13
58	Elevated levels of circulating CD44 in patients with systemic sclerosis: association with a milder subset. British Journal of Rheumatology, 2002, 41, 1149-1154.	2.3	11
59	Idiopathic Intracranial Hypertension with Elevated Cerebrospinal Fluid Level of Interleukin-6 in a Patient with Systemic Lupus Erythematosus. Clinical Rheumatology, 2002, 21, 267-268.	2.2	11
60	P-Selectin Glycoprotein Ligand-1 Contributes to Wound Healing Predominantly as a P-Selectin Ligand and Partly as an E-Selectin Ligand. Journal of Investigative Dermatology, 2009, 129, 2059-2067.	0.7	11
61	Autoantibody against caspase-3, an executioner of apoptosis, in patients with systemic sclerosis. Rheumatology International, 2010, 30, 871-878.	3.0	10
62	Ultraviolet Light Exposure Suppresses Contact Hypersensitivity by Abrogating Endothelial Intercellular Adhesion Molecule-1 Up-Regulation at the Elicitation Site. Journal of Immunology, 2003, 171, 2855-2862.	0.8	9
63	The roles of P- and E-selectins and P-selectin glycoprotein ligand-1 in primary and metastatic mouse melanomas. Journal of Dermatological Science, 2011, 64, 99-107.	1.9	9
64	Involvement of gaseous low molecular monoxides in the cutaneous reverse passive Arthus reaction: cytoprotective action of carbon monoxide. Clinical and Experimental Immunology, 2008, 153, 245-257.	2.6	7
65	Elevated Serum Concentrations of Triggering Receptor Expressed on Myeloid Cells-1 in Diffuse Cutaneous Systemic Sclerosis: Association with Severity of Pulmonary Fibrosis. Journal of Rheumatology, 2010, 37, 787-791.	2.0	6
66	Antigen specificity of antihistone antibodies in connective tissue disease patients with anti-U1RNP antibodies. Rheumatology International, 2007, 28, 113-119.	3.0	4
67	Clinical association of serum CD137 (4-1BB) levels in patients with systemic sclerosis. Journal of Dermatological Science, 2009, 53, 159-161.	1.9	3
68	Low Zone Tolerance Requires ICAM-1 Expression to Limit Contact Hypersensitivity Elicitation. Journal of Investigative Dermatology, 2009, 129, 2661-2667.	0.7	2
69	Three Cases of Juvenile Systemic Sclerosis. Nishinihon Journal of Dermatology, 2008, 70, 371-376.	0.0	1
70	A Case of Child-Onset Eosinophilic Fasciitis. Nishinihon Journal of Dermatology, 2008, 70, 614-617.	0.0	1
71	Augmented interferon I signaling in a patient with COVID toes. Journal of Dermatology, 2021, 48, e242-e243.	1.2	0
72	A Case of Squamous Cell Carcinoma Arising from Discoid Lupus Erythematosus on the Sole. Nishinihon Journal of Dermatology, 2008, 70, 23-26.	0.0	0